ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Respiratory · Eur Respir J · 2026-10-22

In a self-controlled case series of 480 US adults with severe asthma, biologic exposure was associated with fewer severe exacerbations (IRR 0.43, 95% CI 0.39-0.48), similar to a meta-analysis of 6 RCTs (rate ratio 0.53); effects were larger in those meeting some trial criteria.

Meta-analysisn = 480
Boakye-Dankwa et al. A self-controlled case series to evaluate the effects of clinical trial eligibility criteria on biologic-associated reductions in severe asthma exacerbations: an analysis of the CHRONICLE study
Respiratory · Eur Respir Rev · 2026-01-14

Meta-analysis of 16 RCTs (3598 patients) with comorbid asthma and chronic rhinosinusitis with nasal polyps: biologics cut asthma exacerbations by 73% (rate ratio 0.27) and improved FEV1, asthma control and nasal polyp scores, with a favourable safety profile.

Meta-analysisn = 3,598
Kyriakopoulos et al. Efficacy of biologic agents in patients with comorbid asthma and chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.